Results 101 to 110 of about 3,086,863 (251)

PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and tamoxifen in a luminal: A breast cancer model

Molecular Oncology, EarlyView.
Breast cancer remains a major cause of cancer death in women, frequently developing endocrine therapy resistance. This study demonstrates that upregulated p21‐activated kinase 1 (PAK1) activity drives resistance to tamoxifen and long‐term estrogen deprivation in ER+ breast cancer models.
Luisa Schwarzmüller, Janina Müller, Efstathios‐Iason Vlachavas, Lukas Beumers, Lena Fleischhacker, Sara Burmester, Angelika Wörner, Sabine Karolus, Dominic Helm, Cindy Körner, Stefan Wiemann   +10 more
wiley   +1 more source

Cellular, Molecular and Functional Characterization of the Tumor Suppressor Candidate MYO1C [Elektronisk resurs]

, 2016
Tumor suppressor genes play a role as a growth regulator and a gatekeeper of a cell. Their inactivation is often detected in malignant tumors. Identification of novel tumor suppressor gene candidates may help to further understand tumorigenesis and aid ...
Haucke, Volker,, Oldfors, Anders,, Behboudi, Afrouz,, Ejeskär, Katarina,, Visuttijai, Kittichate,   +4 more
core  

Point mutations of the P53 gene, human hepatocellular carcinoma and aflatoxins [PDF]

, 1993
The tumor suppressor p53 exerts important protective functions towards DNA-damaging agents. Its inactivation by allelic deletions or point mutations within the P53 gene as well as complex formation of wildtype p53 with cellular or viral proteins is a ...
Caselmann, Wolfgang H., Gerbes, Alexander L.   +1 more
core   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source

Circulating microRNA signatures of cachexia and cancer in Canis familiaris as a comparative oncology model for human disease

Molecular Oncology, EarlyView.
Circulating microRNAs as biomarkers of cachexia and sex‐specific cancer in senior dogs. In 25 client‐owned dogs, four circulating miRNAs (miR‐15a, miR‐15b, miR‐16, miR‐140) were downregulated in cachexia, with miR‐16 the strongest individual biomarker (AUC = 0.899).
Soon‐Seok Park, Kyongman An, Gyeonghwa Kim, Soo‐Nyun Choi, Hong‐Ki Lee, Keun Hur, Kyu‐Shik Jeong   +6 more
wiley   +1 more source

A global view of the oncogenic landscape in nasopharyngeal carcinoma : an integrated analysis at the genetic and expression levels [PDF]

, 2012
Previous studies have reported that the tumour cells of nasopharyngeal carcinoma (NPC) exhibit recurrent chromosome abnormalities. These genetic changes are broadly assumed to lead to changes in gene expression which are important for the pathogenesis of
Aicha Amari, Murray, Paul G, Dawson, Christopher W, Wei, Wenbin, Xiaoyi Chen (150873), Sim K. Sihota (150887), Shao, Jian-Yong, Andrew I Bell, Maloney, S.L., Nicholls, John M, Shao, J.Y., Aicha Amari (150894), Hu, C., K Dalia Derkaoui, Stephanie L Maloney, Wei, W., Arrand, J.R., Wenbin Wei (150871), Woodman, C.B., Sihota, Sim K, Murray, P.G., Ciaran B. Woodman (150878), Derkaoui, K.D., Ciaran B Woodman, Jian-Yong Shao (41845), Maloney, Stephanie L., Bell, Andrew I., Dawson, Christopher W., John M. Nicholls (150882), Derkaoui, K Dalia, Derkaoui, K. Dalia, Maloney, Stephanie L, Bell, A.I., Sihota, Sim K., Xiaoyi Chen, Lawrence S. Young (150912), Woodman, Ciaran B. J., Nicholls, J.M., Arrand, J. R. (John R.), Irène Joab (150885), Joab, Irène, Amari, Aicha, Arrand, John R, Woodman, Ciaran B, Wenbin Wei, Paul G. Murray (150907), Christopher W. Dawson (150910), Chen, X., Yao, Yunhong, Chunfang Hu, Dawson, C.W., Chunfang Hu (150868), K. Dalia Derkaoui (150892), Andrew I. Bell (150904), Chen, Xiaoyi, Young, Lawrence S., Joab, I., John R. Arrand (150915), Irène Joab, Christopher W Dawson, Nicholls, J. M. (John M.), Stephanie L. Maloney (150899), Yunhong Yao, Wei, Wenbin; id_orcid, Young, Lawrence S, Lawrence S Young, John R Arrand, John M Nicholls, Paul G Murray, Amari, A., Jian-Yong Shao, Bell, Andrew I; id_orcid, Yao, Y., Yunhong Yao (150880), Hu, Chunfang, Young, L.S., Sihota, S.K., Murray, Paul G., Sim K Sihota   +78 more
core   +2 more sources

Aberrant promoter methylation in p53 and ATM genes was not associated with sporadic breast carcinogenesis in Bulgarian patients [PDF]

Journal of BioScience and Biotechnology, 2014
Epigenetic silencing of gene expression has become an intensively studied topic regarding breast cancer during the last years. Previous investigations have shown that hypermethylation in gene promoters is an alternative to mutations cancer-related ...
MARIA E. KRASTEVA, GEORGI G. ANTOV, ZLATINA I. GOSPODINOVA, SVETLA G. ANGELOVA, MARIA B. NACHEVA, ELENA I. GEORGIEVA, IVAN G. GAVRILOV   +6 more
doaj  

Cancer‐associated mutations in endometriosis reframe a benign disease through molecular oncology

Molecular Oncology, EarlyView.
This review aims to comprehensively analyse cancer‐associated somatic mutations (CAMs) present in endometriotic lesions, emphasizing their biological roles, spatial distribution and implications for translational applications in medicine. By contextualizing a benign state within a genomic framework, this analysis seeks to establish its value as a ...
Clarissa Mujacic, Maria Concetta Vitale, Rita Siino, Emilia Di Giovanni, Carla Ferrante Bannera, Enrico Di Marco, Andrea Gottardo, Tancredi Didier Bazan Russo, Nadia Barraco, Alessandro Perez, Valerio Gristina, Antonio Galvano, Giuseppe Badalamenti, Antonio Russo, Viviana Bazan, Lorena Incorvaia   +15 more
wiley   +1 more source

Epigenetic silencing of the liver‐specific lncRNA LUNAR promotes liver cancer progression via NOTCH activation

Molecular Oncology, EarlyView.
LUNAR is a liver‐specific long noncoding RNA (lncRNA) that is highly expressed in normal liver but becomes epigenetically silenced in hepatocellular carcinoma through promoter hypermethylation. Loss of LUNAR is associated with NOTCH activation, epithelial–mesenchymal transition, and metastasis, whereas restoring LUNAR restrains metastatic progression ...
Se Ha Jang, Hyung Seok Kim, Geum Ok Baek, Moon Gyeong Yoon, Su In Lee, Jee‐Yeong Jeong, Ji Eun Han, Soon Sun Kim, Jae Youn Cheong, Jung Woo Eun   +9 more
wiley   +1 more source

Translating whole‐genome doubling into precision medicine in cancer

Molecular Oncology, EarlyView.
Whole‐genome doubling creates a WGD‐positive tumor state characterized by persistent chromosomal instability, karyotypic diversification, and cellular stress. These same biological pressures drive aggressive tumor evolution while exposing therapeutic vulnerabilities, providing a rationale for WGD‐informed precision medicine. Whole‐genome doubling (WGD)
Sejung Lee, Junghyeok Lim, Jinhyuk Bhin
wiley   +1 more source